Stifel analyst Annabel Samimy raised the firm’s price target on Oculis (OCS) to $40 from $35 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst’s Biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS: